Liquidia Corporation LQDA Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| Program Expenses by Product | |||
| Generic Treprostinil | $364K-49.4% | $720K+134% | |
| L606 | $19.68M+63.3% | $12.05M-4.0% | |
| Yutrepia | $55.44M+48.4% | $37.35M+59.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Liquidia Corporation break its business down?
- Liquidia Corporation (LQDA) reports program expenses by product across 3 parts — Generic Treprostinil, L606 and Yutrepia. Each is extracted from the segment footnotes and tracked over time.
- Where does Liquidia Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Liquidia Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
